Landos Biopharma Inc (LABP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 29,054 | 37,549 | 42,458 | 44,049 | 45,244 |
| Marketable Securities | N/A | N/A | 62 | 687 | 4,762 |
| TOTAL | $29,896 | $38,040 | $43,230 | $46,285 | $51,184 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $29,896 | $38,040 | $43,230 | $46,285 | $51,184 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,565 | 1,375 | 1,135 | 1,029 | 2,298 |
| Accrued Expenses | 5,177 | 4,874 | 4,431 | 1,986 | 1,862 |
| TOTAL | $6,742 | $6,249 | $5,566 | $3,015 | $4,160 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $6,742 | $6,249 | $5,566 | $3,015 | $4,160 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 3,126 | 3,117 | 3,117 | 3,117 | 3,117 |
| Common Shares | 31 | 31 | 31 | 31 | 312 |
| Retained earnings | -164,259 | -155,362 | -149,243 | -143,383 | -139,461 |
| Other shareholders' equity | 0 | 0 | -1 | -7 | 79 |
| TOTAL | $23,154 | $31,791 | $37,664 | $43,270 | $47,024 |
| Total Liabilities And Equity | $29,896 | $38,040 | $43,230 | $46,285 | $51,184 |